Heat shock transcription factor 1 as a therapeutic target in neurodegenerative diseases

Nature Reviews Drug Discovery

Volumn 10, Issue 12, 2011, Pages 930-944

  Neef, Daniel W ^a   Jaeger, Alex M ^a   Thiele, Dennis J ^a  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AEG 3482; ALVESPIMYCIN; ARIMOCLOMOL; BIMOCLOMOL; BRX 220; CARBENOXOLONE; CELASTROL; CHAPERONE; EPIGALLOCATECHIN GALLATE; GEDUNIN; GELDANAMYCIN; HEAT SHOCK PROTEIN 90 INHIBITOR; HEAT SHOCK TRANSCRIPTION FACTOR 1; HEAT SHOCK TRANSCRIPTION FACTOR 1A; INDOMETACIN; ITZ 1; NABUMETONE; NONSTEROID ANTIINFLAMMATORY AGENT; NOVOBIOCIN; POLAPREZINC; PYRAZOLE DERIVATIVE; REBAMIPIDE; RILUZOLE; SALICYLATE SODIUM; SULINDAC; TANESPIMYCIN; TEPRENONE; UNCLASSIFIED DRUG;

ACETYLATION; ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; BLOOD BRAIN BARRIER; CELL STRESS; CLINICAL TRIAL (TOPIC); DEGENERATIVE DISEASE; DISEASE ASSOCIATION; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; DRUG PENETRATION; DRUG STRUCTURE; DRUG TARGETING; GASTROINTESTINAL TOXICITY; GENE EXPRESSION; HUMAN; HUNTINGTON CHOREA; LIVER TOXICITY; MICROARRAY ANALYSIS; MOLECULAR INTERACTION; NERVE CELL NECROSIS; NEUROPATHY; NONHUMAN; PARKINSON DISEASE; PRION DISEASE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DNA BINDING; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN METABOLISM; PROTEIN MODIFICATION; PROTEIN TRANSPORT; REVIEW; SIGNAL TRANSDUCTION; SUMOYLATION;

ANIMALS; DNA-BINDING PROTEINS; DRUG DELIVERY SYSTEMS; HEAT-SHOCK PROTEINS; HUMANS; NEURODEGENERATIVE DISEASES; TRANSCRIPTION FACTORS;

EID: 82455210670     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd3453     Document Type: Review

References (183)

1. Ross, C. A. & Poirier, M. A. Protein aggregation and neurodegenerative disease. Nature Med. 10, S10-S17 (2004).
2. Zhang, Q. C. et al. A compact β model of huntingtin toxicity. J. Biol. Chem. 286, 8188-8196 (2011).
3. Haass, C. & Selkoe, D. J. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide. Nature Rev. Mol. Cell Biol. 8, 101-112 (2007).
4. Muchowski, P. J. Protein misfolding, amyloid formation, and neurodegeneration: a critical role for molecular chaperones? Neuron 35, 9-12 (2002).
5. Arrasate, M., Mitra, S., Schweitzer, E. S., Segal, M. R. & Finkbeiner, S. Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature 431, 805-810 (2004).
6. Fiumara, F., Fioriti, L., Kandel, E. R. & Hendrickson, W. A. Essential role of coiled coils for aggregation and activity of Q/N-rich prions and polyQ proteins. Cell 143, 1121-1135 (2010). This study demonstrated that coiled-coil motifs in polyQ proteins contribute to the aggregation and cytotoxicity of these proteins.
7. Cookson, M. R. The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease. Nature Rev. Neurosci. 11, 791-797 (2010).
8. Jankovic, J. Parkinson's disease: clinical features and diagnosis. J. Neurol. Neurosurg. Psychiatr. 79, 368-376 (2008).
9. Buschert, V., Bokde, A. L. W. & Hampel, H. Cognitive intervention in Alzheimer disease. Nature Rev. Neurol. 6, 508-517 (2010).
10. Carter, M. D., Simms, G. A. & Weaver, D. F. The development of new therapeutics for Alzheimer's disease. Clin. Pharmacol. Ther. 88, 475-486 (2010).
11. Boillée, S., Vande Velde, C. & Cleveland, D. W. ALS: a disease of motor neurons and their nonneuronal neighbors. Neuron 52, 39-59 (2006).
12. Verity, N. C. & Mallucci, G. R. Rescuing neurons in prion disease. Biochem. J. 433, 19-29 (2010).
13. Walker, F. O. Huntington's disease. Lancet 369, 218-228 (2007).
14. Hartl, F. U. & Hayer-Hartl, M. Molecular chaperones in the cytosol: from nascent chain to folded protein. Science 295, 1852-1858 (2002).
15. Chai, Y., Koppenhafer, S. L., Bonini, N. M. & Paulson, H. L. Analysis of the role of heat shock protein (Hsp) molecular chaperones in polyglutamine disease. J. Neurosci. 19, 10338-10347 (1999).
16. Warrick, J. M. et al. Suppression of polyglutamine-mediated neurodegeneration in Drosophila by the molecular chaperone HSP70. Nature Genet. 23, 425-428 (1999).
17. Chan, H. Y., Warrick, J. M., Gray-Board, G. L., Paulson, H. L. & Bonini, N. M. Mechanisms of chaperone suppression of polyglutamine disease: selectivity, synergy and modulation of protein solubility in Drosophila. Hum. Mol. Genet. 9, 2811-2820 (2000). This study showed that HSP40 and HSP70 synergize to ameliorate the cytotoxicity of polyQ proteins in fruitfly disease models by modulating the solubility of these proteins.
18. Auluck, P. K. & Bonini, N. M. Pharmacological prevention of Parkinson disease in Drosophila. Nature Med. 8, 1185-1186 (2002). This paper showed that pharmacological activation of HSF1 via the HSP90 inhibitor geldanamycin can ameliorate disease phenotypes in a fruitfly model of Parkinson's disease.
19. Auluck, P., Meulener, M. & Bonini, N. Mechanisms of suppression of α-synuclein neurotoxicity by geldanamycin in Drosophila. J. Biol. Chem. 280, 2873-2878 (2005).
20. Alavez, S., Vantipalli, M. C., Zucker, D. J., Klang, I. M. & Lithgow, G. J. Amyloid-binding compounds maintain protein homeostasis during ageing and extend lifespan. Nature 472, 226-229 (2011).
21. Ben-Zvi, A., Miller, E. A. & Morimoto, R. I. Collapse of proteostasis represents an early molecular event in Caenorhabditis elegans aging. Proc. Natl Acad. Sci. USA 106, 14914-14919 (2009). This study describes a widespread failure in protein folding that occurs in early adulthood and coincides with reduced activation of HSF1 and chaperone protein expression in C. elegans.
22. Fonte, V. et al. Interaction of intracellular β amyloid peptide with chaperone proteins. Proc. Natl Acad. Sci. USA 99, 9439-9444 (2002).
23. Satyal, S. H. et al. Polyglutamine aggregates alter protein folding homeostasis in Caenorhabditis elegans. Proc. Natl Acad. Sci. USA 97, 5750-5755 (2000). This study shows that the expression of polyQ proteins in C. elegans disrupts general protein folding, causes aggregation of otherwise soluble proteins and constitutively promotes the activation of HSF1 and chaperone proteins.
24. Teixeira-Castro, A. et al. Neuron-specific proteotoxicity of mutant ataxin-3 in C. elegans: rescue by the DAF-16 and HSF-1 pathways. Hum. Mol. Genet. 20, 2996-3009 (2011).
25. Wang, J. et al. An ALS-linked mutant SOD1 produces a locomotor defect associated with aggregation and synaptic dysfunction when expressed in neurons of Caenorhabditis elegans. PLoS Genet. 5, e1000350 (2009).
26. Lanneau, D., de Thonel, A., Maurel, S., Didelot, C. & Garrido, C. Apoptosis versus cell differentiation: role of heat shock proteins HSP90, HSP70 and HSP27. Prion 1, 53-60 (2007).
27. Batulan, Z. et al. High threshold for induction of the stress response in motor neurons is associated with failure to activate HSF1. J. Neurosci. 23, 5789-5798 (2003).
28. Bonelli, M. A. et al. Attenuated expression of 70-kDa heat shock protein in WI-38 human fibroblasts during aging in vitro. Exp. Cell Res. 252, 20-32 (1999).
29. Gutsmann-Conrad, A., Heydari, A. R., You, S. & Richardson, A. The expression of heat shock protein 70 decreases with cellular senescence in vitro and in cells derived from young and old human subjects. Exp. Cell Res. 241, 404-413 (1998).
30. Gutsmann-Conrad, A., Pahlavani, M. A., Heydari, A. R. & Richardson, A. Expression of heat shock protein 70 decreases with age in hepatocytes and splenocytes from female rats. Mech. Ageing Dev. 107, 255-270 (1999).
31. Fargnoli, J., Kunisada, T., Fornace, A. J., Schneider, E. L. & Holbrook, N. J. Decreased expression of heat shock protein 70 mRNA and protein after heat treatment in cells of aged rats. Proc. Natl Acad. Sci. USA 87, 846-850 (1990).
32. Fawcett, T. W., Sylvester, S. L., Sarge, K. D., Morimoto, R. I. & Holbrook, N. J. Effects of neurohormonal stress and aging on the activation of mammalian heat shock factor 1. J. Biol. Chem. 269, 32272-32278 (1994).
33. Pahlavani, M. A., Harris, M. D., Moore, S. A., Weindruch, R. & Richardson, A. The expression of heat shock protein 70 decreases with age in lymphocytes from rats and rhesus monkeys. Exp. Cell Res. 218, 310-318 (1995).
34. Bailey, C. K., Andriola, I. F. M., Kampinga, H. H. & Merry, D. E. Molecular chaperones enhance the degradation of expanded polyglutamine repeat androgen receptor in a cellular model of spinal and bulbar muscular atrophy. Hum. Mol. Genet. 11, 515-523 (2002).
35. Fujimoto, M. et al. Active HSF1 significantly suppresses polyglutamine aggregate formation in cellular and mouse models. J. Biol. Chem. 280, 34908-34916 (2005). This study demonstrates that the expression of a constitutively active HSF1 allele ameliorates pathogenic phenotypes in a mouse model of Huntington's disease.
36. Muchowski, P. J. et al. Hsp70 and Hsp40 chaperones can inhibit self-assembly of polyglutamine proteins into amyloid-like fibrils. Proc. Natl Acad. Sci. USA 97, 7841-7846 (2000).
37. Wacker, J. L., Zareie, M. H., Fong, H., Sarikaya, M. & Muchowski, P. J. Hsp70 and Hsp40 attenuate formation of spherical and annular polyglutamine oligomers by partitioning monomer. Nature Struct. Mol. Biol. 11, 1215-1222 (2004).
38. Wyttenbach, A. et al. Effects of heat shock, heat shock protein 40 (HDJ-2), and proteasome inhibition on protein aggregation in cellular models of Huntington's disease. Proc. Natl Acad. Sci. USA 97, 2898-2903 (2000).
39. Feder, J. H., Rossi, J. M., Solomon, J., Solomon, N. & Lindquist, S. The consequences of expressing hsp70 in Drosophila cells at normal temperatures. Genes Dev. 6, 1402-1413 (1992).
40. Dai, C., Whitesell, L., Rogers, A. B. & Lindquist, S. Heat shock factor 1 is a powerful multifaceted modifier of carcinogenesis. Cell 130, 1005-1018 (2007).
41. Akerfelt, M., Morimoto, R. I. & Sistonen, L. Heat shock factors: integrators of cell stress, development and lifespan. Nature Rev. Mol. Cell Biol. 11, 545-555 (2010).
42. Gonsalves, S. E., Moses, A. M., Razak, Z., Robert, F. & Westwood, J. T. Whole-genome analysis reveals that active heat shock factor binding sites are mostly associated with non-heat shock genes in Drosophila melanogaster. PLoS ONE 6, e15934 (2011).
43. Hahn, J.-S., Hu, Z., Thiele, D. J. & Iyer, V. R. Genome-wide analysis of the biology of stress responses through heat shock transcription factor. Mol. Cell Biol. 24, 5249-5256 (2004).
44. Trinklein, N. D., Murray, J. I., Hartman, S. J., Botstein, D. & Myers, R. M. The role of heat shock transcription factor 1 in the genome-wide regulation of the mammalian heat shock response. Mol. Biol. Cell 15, 1254-1261 (2004).
45. Ostling, P., Björk, J. K., Roos-Mattjus, P., Mezger, V. & Sistonen, L. Heat shock factor 2 (HSF2) contributes to inducible expression of hsp genes through interplay with HSF1. J. Biol. Chem. 282, 7077-7086 (2007).
46. Sandqvist, A. et al. Heterotrimerization of heat-shock factors 1 and 2 provides a transcriptional switch in response to distinct stimuli. Mol. Biol. Cell 20, 1340-1347 (2009).
47. Shinkawa, T. et al. Heat shock factor 2 is required for maintaining proteostasis against febrile range thermal stress and polyglutamine aggregation. Mol. Biol. Cell 22, 3571-3583 (2011).
48. Abravaya, K., Myers, M. P., Murphy, S. P. & Morimoto, R. I. The human heat shock protein hsp70 interacts with HSF, the transcription factor that regulates heat shock gene expression. Genes Dev. 6, 1153-1164 (1992).
49. Ali, A., Bharadwaj, S., O'Carroll, R. & Ovsenek, N. HSP90 interacts with and regulates the activity of heat shock factor 1 in Xenopus oocytes. Mol. Cell Biol. 18, 4949-4960 (1998).
50. Bharadwaj, S., Ali, A. & Ovsenek, N. Multiple components of the HSP90 chaperone complex function in regulation of heat shock factor 1 in vivo. Mol. Cell Biol. 19, 8033-8041 (1999).
51. Conde, R., Xavier, J., McLoughlin, C., Chinkers, M. & Ovsenek, N. Protein phosphatase 5 is a negative modulator of heat shock factor 1. J. Biol. Chem. 280, 28989-28996 (2005).
52. Guo, Y. et al. Evidence for a mechanism of repression of heat shock factor 1 transcriptional activity by a multichaperone complex. J. Biol. Chem. 276, 45791-45799 (2001).
53. Shi, Y., Mosser, D. D. & Morimoto, R. I. Molecular chaperones as HSF1-specific transcriptional repressors. Genes Dev. 12, 654-666 (1998).
54. Zou, J., Guo, Y., Guettouche, T., Smith, D. F. & Voellmy, R. Repression of heat shock transcription factor HSF1 activation by HSP90 (HSP90 complex) that forms a stress-sensitive complex with HSF1. Cell 94, 471-480 (1998).
55. Arlander, S. J. H. et al. Chaperoning checkpoint kinase 1 (Chk1), an Hsp90 client, with purified chaperones. J. Biol. Chem. 281, 2989-2998 (2006).
56. Hernéndez, M. P., Chadli, A. & Toft, D. O. HSP40 binding is the first step in the HSP90 chaperoning pathway for the progesterone receptor. J. Biol. Chem. 277, 11873-11881 (2002).
57. King, F. W., Wawrzynow, A., Höhfeld, J. & Zylicz, M. Co-chaperones Bag-1, Hop and Hsp40 regulate Hsc70 and Hsp90 interactions with wild-type or mutant p53. EMBO J. 20, 6297-6305 (2001).
58. Carmichael, J., Sugars, K. L., Bao, Y. P. & Rubinsztein, D. C. Glycogen synthase kinase-3β inhibitors prevent cellular polyglutamine toxicity caused by the Huntington's disease mutation. J. Biol. Chem. 277, 33791-33798 (2002).
59. Chu, B., Soncin, F., Price, B. D., Stevenson, M. A. & Calderwood, S. K. Sequential phosphorylation by mitogen-activated protein kinase and glycogen synthase kinase 3 represses transcriptional activation by heat shock factor-1. J. Biol. Chem. 271, 30847-30857 (1996).
60. Chu, B., Zhong, R., Soncin, F., Stevenson, M. A. & Calderwood, S. K. Transcriptional activity of heat shock factor 1 at 37 °C is repressed through phosphorylation on two distinct serine residues by glycogen synthase kinase 3 and protein kinases C? and C?. J. Biol. Chem. 273, 18640-18646 (1998).
61. Hietakangas, V. et al. Phosphorylation of serine 303 is a prerequisite for the stress-inducible SUMO modification of heat shock factor 1. Mol. Cell Biol. 23, 2953-2968 (2003).
62. Kline, M. P. & Morimoto, R. I. Repression of the heat shock factor 1 transcriptional activation domain is modulated by constitutive phosphorylation. Mol. Cell Biol. 17, 2107-2115 (1997).
63. Knauf, U., Newton, E. M., Kyriakis, J. & Kingston, R. E. Repression of human heat shock factor 1 activity at control temperature by phosphorylation. Genes Dev. 10, 2782-2793 (1996).
64. Murshid, A. et al. Protein kinase A binds and activates heat shock factor 1. PLoS ONE 5, e13830 (2010).
65. Wang, X. et al. Phosphorylation of HSF1 by MAPK-activated protein kinase 2 on serine 121, inhibits transcriptional activity and promotes HSP90 binding. J. Biol. Chem. 281, 782-791 (2006).
66. Pelham, H. R. A regulatory upstream promoter element in the Drosophila Hsp 70 heat-shock gene. Cell 30, 517-528 (1982).
67. Pelham, H. R. & Bienz, M. A synthetic heat-shock promoter element confers heat-inducibility on the herpes simplex virus thymidine kinase gene. EMBO J. 1, 1473-1477 (1982).
68. Perisic, O., Xiao, H. & Lis, J. T. Stable binding of Drosophila heat shock factor to head-to-head and tail-to-tail repeats of a conserved 5 bp recognition unit. Cell 59, 797-806 (1989).
69. Clos, J. et al. Molecular cloning and expression of a hexameric Drosophila heat shock factor subject to negative regulation. Cell 63, 1085-1097 (1990).
70. Sorger, P. K. & Nelson, H. C. Trimerization of a yeast transcriptional activator via a coiled-coil motif. Cell 59, 807-813 (1989).
71. Ahn, S.-G. & Thiele, D. J. Redox regulation of mammalian heat shock factor 1 is essential for Hsp gene activation and protection from stress. Genes Dev. 17, 516-528 (2003).
72. Neef, D. W., Turski, M. L. & Thiele, D. J. Modulation of heat shock transcription factor 1 as a therapeutic target for small molecule intervention in neurodegenerative disease. PLoS Biol. 8, e1000291 (2010). In this study the authors generated a humanized HSF1-based yeast screen to identify HSF1A, a novel pharmacological activator of HSF1 that is efficacious in ameliorating polyQ protein-associated protein aggregation and cytotoxicity in cell culture and fruitfly disease models.
73. Trott, A. et al. Activation of heat shock and antioxidant responses by the natural product celastrol: transcriptional signatures of a thiol-targeted molecule. Mol. Biol. Cell 19, 1104-1112 (2008).
74. Rabindran, S. K., Haroun, R. I., Clos, J., Wisniewski, J. & Wu, C. Regulation of heat shock factor trimer formation: role of a conserved leucine zipper. Science 259, 230-234 (1993).
75. Guettouche, T., Boellmann, F., Lane, W. S. & Voellmy, R. Analysis of phosphorylation of human heat shock factor 1 in cells experiencing a stress. BMC Biochem. 6, 4 (2005).
76. Holmberg, C. I. et al. Phosphorylation of serine 230 promotes inducible transcriptional activity of heat shock factor 1. EMBO J. 20, 3800-3810 (2001).
77. Kim, S.-A., Yoon, J.-H., Lee, S.-H. & Ahn, S.-G. Polo-like kinase 1 phosphorylates heat shock transcription factor 1 and mediates its nuclear translocation during heat stress. J. Biol. Chem. 280, 12653-12657 (2005).
78. Westerheide, S. D., Anckar, J., Stevens, S. M., Sistonen, L. & Morimoto, R. I. Stress-inducible regulation of heat shock factor 1 by the deacetylase SIRT1. Science 323, 1063-1066 (2009). This study demonstrated that the DNA binding activity of HSF1 is inhibited by acetylation within the DNA binding domain, and HSF1 is maintained in a deacetylated state via SIRT1.
79. Yang, J., Bridges, K., Chen, K. Y. & Liu, A. Y.-C. Riluzole increases the amount of latent HSF1 for an amplified heat shock response and cytoprotection. PLoS ONE 3, e2864 (2008). This work reported that riluzole, which is a treatment for ALS, promotes an increase in steady-state HSF1 levels potentially via the inhibition of chaperone-mediated autophagy.
80. Trepel, J., Mollapour, M., Giaccone, G. & Neckers, L. Targeting the dynamic HSP90 complex in cancer. Nature Rev. Cancer 10, 537-549 (2010).
81. Dickey, C. A. et al. HSP induction mediates selective clearance of tau phosphorylated at proline-directed Ser/Thr sites but not KXGS (MARK) sites. FASEB J. 20, 753-755 (2006).
82. Dickey, C. A. et al. Development of a high throughput drug screening assay for the detection of changes in tau levels - proof of concept with HSP90 inhibitors. Curr. Alzheimer Res. 2, 231-238 (2005).
83. Dou, F. et al. Chaperones increase association of tau protein with microtubules. Proc. Natl Acad. Sci. USA 100, 721-726 (2003).
84. Petrucelli, L. et al. CHIP and Hsp70 regulate tau ubiquitination, degradation and aggregation. Hum. Mol. Genet. 13, 703-714 (2004).
85. Flower, T. R., Chesnokova, L. S., Froelich, C. A., Dixon, C. & Witt, S. N. Heat shock prevents α-synuclein-induced apoptosis in a yeast model of Parkinson's disease. J. Mol. Biol. 351, 1081-1100 (2005).
86. Shen, H.-Y., He, J.-C., Wang, Y., Huang, Q.-Y. & Chen, J.-F. Geldanamycin induces heat shock protein 70 and protects against MPTP-induced dopaminergic neurotoxicity in mice. J. Biol. Chem. 280, 39962-39969 (2005).
87. Agrawal, N. et al. Identification of combinatorial drug regimens for treatment of Huntington's disease using Drosophila. Proc. Natl Acad. Sci. USA 102, 3777-3781 (2005). This study demonstrated that the HSP90 inhibitor geldanamycin and the histone deacetylase inhibitor suberoylanilide hydroxamic acid have combinatorial efficacy in ameliorating cytotoxicity in a fruitfly model of neurodegenerative disease.
88. Fujikake, N. et al. Heat shock transcription factor 1-activating compounds suppress polyglutamine-induced neurodegeneration through induction of multiple molecular chaperones. J. Biol. Chem. 283, 26188-26197 (2008).
89. Hay, D. G. et al. Progressive decrease in chaperone protein levels in a mouse model of Huntington's disease and induction of stress proteins as a therapeutic approach. Hum. Mol. Genet. 13, 1389-1405 (2004).
90. Sittler, A. et al. Geldanamycin activates a heat shock response and inhibits huntingtin aggregation in a cell culture model of Huntington's disease. Hum. Mol. Genet. 10, 1307-1315 (2001).
91. Marcu, M. G., Chadli, A., Bouhouche, I., Catelli, M. & Neckers, L. M. The heat shock protein 90 antagonist novobiocin interacts with a previously unrecognized ATP-binding domain in the carboxyl terminus of the chaperone. J. Biol. Chem. 275, 37181-37186 (2000).
92. Yu, X. M. et al. Hsp90 inhibitors identified from a library of novobiocin analogues. J. Am. Chem. Soc. 127, 12778-12779 (2005).
93. Ansar, S. et al. A non-toxic Hsp90 inhibitor protects neurons from Aβ-induced toxicity. Bioorg. Med. Chem. Lett. 17, 1984-1990 (2007).
94. Kimura, H. et al. ITZ-1, a client-selective Hsp90 inhibitor, efficiently induces heat shock factor 1 activation. Chem. Biol. 17, 18-27 (2010).
95. Salehi, A. H. et al. AEG3482 is an antiapoptotic compound that inhibits Jun kinase activity and cell death through induced expression of heat shock protein 70. Chem. Biol. 13, 213-223 (2006).
96. Schnaider, T., Somogyi, J., Csermely, P. & Szamel, M. The Hsp90-specific inhibitor, geldanamycin, blocks CD28-mediated activation of human T lymphocytes. Life Sci. 63, 949-954 (1998).
97. Westerheide, S. et al. Celastrols as inducers of the heat shock response and cytoprotection. J. Biol. Chem. 279, 56053-56060 (2004).
98. Hieronymus, H. et al. Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulators. Cancer Cell 10, 321-330 (2006).
99. Zhang, T. et al. A novel Hsp90 inhibitor to disrupt Hsp90/Cdc37 complex against pancreatic cancer cells. Mol. Cancer Ther. 7, 162-170 (2008).
100. Yang, H., Chen, D., Cui, Q. C., Yuan, X. & Dou, Q. P. Celastrol, a triterpene extracted from the Chinese "Thunder of God Vine," is a potent proteasome inhibitor and suppresses human prostate cancer growth in nude mice. Cancer Res. 66, 4758-4765 (2006).
101. Kiaei, M. et al. Celastrol blocks neuronal cell death and extends life in transgenic mouse model of amyotrophic lateral sclerosis. Neurodegener. Dis. 2, 246-254 (2005).
102. Allison, A. C., Cacabelos, R., Lombardi, V. R., Alvarez, X. A. & Vigo, C. Celastrol, a potent antioxidant and anti-inflammatory drug, as a possible treatment for Alzheimer's disease. Prog. Neuropsychopharmacol. Biol. Psychiatry 25, 1341-1357 (2001).
103. Wang, J., Gines, S., MacDonald, M. E. & Gusella, J. F. Reversal of a full-length mutant huntingtin neuronal cell phenotype by chemical inhibitors of polyglutamine-mediated aggregation. BMC Neurosci. 6, 1 (2005).
104. Zhang, Y.-Q. & Sarge, K. D. Celastrol inhibits polyglutamine aggregation and toxicity though induction of the heat shock response. J. Mol. Med. 85, 1421-1428 (2007).
105. Cleren, C., Calingasan, N. Y., Chen, J. & Beal, M. F. Celastrol protects against MPTP- and 3-nitropropionic acid-induced neurotoxicity. J. Neurochem. 94, 995-1004 (2005).
106. Faust, K. et al. Neuroprotective effects of compounds with antioxidant and anti-inflammatory properties in a Drosophila model of Parkinson's disease. BMC Neurosci. 10, 109 (2009).
107. Hansen, J. & Bross, P. A cellular viability assay to monitor drug toxicity. Methods Mol. Biol. 648, 303-311 (2010).
108. Kalmar, B. & Greensmith, L. Activation of the heat shock response in a primary cellular model of motoneuron neurodegeneration - evidence for neuroprotective and neurotoxic effects. Cell. Mol. Biol. Lett. 14, 319-335 (2009).
109. Wang, S., Liu, K., Wang, X., He, Q. & Chen, X. Toxic effects of celastrol on embryonic development of zebrafish (Danio rerio). Drug Chem. Toxicol. 34, 61-65 (2011).
110. Ohtsuka, K., Kawashima, D., Gu, Y. & Saito, K. Inducers and co-inducers of molecular chaperones. Int. J. Hyperthermia 21, 703-711 (2005).
111. Hirakawa, T., Rokutan, K., Nikawa, T. & Kishi, K. Geranylgeranylacetone induces heat shock proteins in cultured guinea pig gastric mucosal cells and rat gastric mucosa. Gastroenterology 111, 345-357 (1996).
112. Katsuno, M. et al. Pharmacological induction of heat-shock proteins alleviates polyglutamine-mediated motor neuron disease. Proc. Natl Acad. Sci. USA 102, 16801-16806 (2005). This work demonstrated that pharmacological activation of HSF1 via geranylgeranylacetone promotes the activation of chaperone protein expression and ameliorates cytotoxicity in a mouse model of spinal and bulbar muscular atrophy.
113. Otaka, M. et al. The induction mechanism of the molecular chaperone HSP70 in the gastric mucosa by geranylgeranylacetone (HSP-inducer). Biochem. Biophys. Res. Commun. 353, 399-404 (2007).
114. Patury, S., Miyata, Y. & Gestwicki, J. E. Pharmacological targeting of the Hsp70 chaperone. Curr. Top. Med. Chem. 9, 1337-1351 (2009).
115. Hirota, K. et al. Geranylgeranylacetone enhances expression of thioredoxin and suppresses ethanol-induced cytotoxicity in cultured hepatocytes. Biochem. Biophys. Res. Commun. 275, 825-830 (2000).
116. Okada, S. et al. Geranylgeranylacetone induces apoptosis in HL-60 cells. Cell Struct. Funct. 24, 161-168 (1999).
117. Endo, S. et al. Geranylgeranylacetone, an inducer of the 70-kDa heat shock protein (HSP70), elicits unfolded protein response and coordinates cellular fate independently of HSP70. Mol. Pharmacol. 72, 1337-1348 (2007).
118. Tam, S., Geller, R., Spiess, C. & Frydman, J. The chaperonin TRiC controls polyglutamine aggregation and toxicity through subunit-specific interactions. Nature Cell Biol. 8, 1155-1162 (2006). This study shows that the TRIC cytosolic chaperone complex binds to the pathogenic huntingtin protein and reduces huntingtin-mediated cytotoxicity.
119. Tam, S. et al. The chaperonin TRiC blocks a huntingtin sequence element that promotes the conformational switch to aggregation. Nature Struct. Mol. Biol. 16, 1279-1285 (2009).
120. Hargitai, J. et al. Bimoclomol, a heat shock protein co-inducer, acts by the prolonged activation of heat shock factor-1. Biochem. Biophys. Res. Commun. 307, 689-695 (2003).
121. Vígh, L. et al. Bimoclomol: a nontoxic, hydroxylamine derivative with stress protein-inducing activity and cytoprotective effects. Nature Med. 3, 1150-1154 (1997).
122. Török, Z. et al. Heat shock protein coinducers with no effect on protein denaturation specifically modulate the membrane lipid phase. Proc. Natl Acad. Sci. USA 100, 3131-3136 (2003).
123. Nánási, P. P. & Jednákovits, A. Multilateral in vivo and in vitro protective effects of the novel heat shock protein coinducer, bimoclomol: results of preclinical studies. Cardiovasc. Drug Rev. 19, 133-151 (2001).
124. Kalmar, B. et al. Late stage treatment with arimoclomol delays disease progression and prevents protein aggregation in the SOD1G93A mouse model of ALS. J. Neurochem. 107, 339-350 (2008).
125. Kieran, D. et al. Treatment with arimoclomol, a coinducer of heat shock proteins, delays disease progression in ALS mice. Nature Med. 10, 402-405 (2004). This study demonstrates that pharmacological activation of HSF1 via arimoclomol ameliorates pathogenic phenotypes and extends lifespan in a mouse model of ALS.
126. Lanka, V., Wieland, S., Barber, J. & Cudkowicz, M. Arimoclomol: a potential therapy under development for ALS. Expert Opin. Investig. Drugs 18, 1907-1918 (2009).
127. Liu, A. Y. C. et al. Neuroprotective drug riluzole amplifies the heat shock factor 1 (HSF1)- and glutamate transporter 1 (GLT1)-dependent cytoprotective mechanisms for neuronal survival. J. Biol. Chem. 286, 2785-2794 (2011).
128. Jurivich, D. A., Sistonen, L., Kroes, R. A. & Morimoto, R. I. Effect of sodium salicylate on the human heat shock response. Science 255, 1243-1245 (1992).
129. Lee, B. S., Chen, J., Angelidis, C., Jurivich, D. A. & Morimoto, R. I. Pharmacological modulation of heat shock factor 1 by antiinflammatory drugs results in protection against stress-induced cellular damage. Proc. Natl Acad. Sci. USA 92, 7207-7211 (1995).
130. Winegarden, N. A., Wong, K. S., Sopta, M. & Westwood, J. T. Sodium salicylate decreases intracellular ATP, induces both heat shock factor binding and chromosomal puffing, but does not induce hsp 70 gene transcription in Drosophila. J. Biol. Chem. 271, 26971-26980 (1996).
131. Housby, J. N. et al. Non-steroidal anti-inflammatory drugs inhibit the expression of cytokines and induce HSP70 in human monocytes. Cytokine 11, 347-358 (1999).
132. Palayoor, S. T., Youmell, M. Y., Calderwood, S. K., Coleman, C. N. & Price, B. D. Constitutive activation of IκB kinase α and NF-κB in prostate cancer cells is inhibited by ibuprofen. Oncogene 18, 7389-7394 (1999).
133. Stevenson, M. A., Zhao, M. J., Asea, A., Coleman, C. N. & Calderwood, S. K. Salicylic acid and aspirin inhibit the activity of RSK2 kinase and repress RSK2-dependent transcription of cyclic AMP response element binding protein- and NF-? B-responsive genes. J. Immunol. 163, 5608-5616 (1999).
134. Ishihara, K., Yamagishi, N. & Hatayama, T. Suppression of heat- and polyglutamine-induced cytotoxicity by nonsteroidal anti-inflammatory drugs. Eur. J. Biochem. 271, 4552-4558 (2004).
135. Ianaro, A. et al. Anti-inflammatory activity of 15-deoxy-δ12,14- PGJ2 and 2-cyclopenten-1-one: role of the heat shock response. Mol. Pharmacol. 64, 85-93 (2003).
136. Rossi, A., Elia, G. & Santoro, M. G. 2-cyclopenten- 1-one, a new inducer of heat shock protein 70 with antiviral activity. J. Biol. Chem. 271, 32192-32196 (1996).
137. Zhou, Y. et al. Chloro-oxime derivatives as novel small molecule chaperone amplifiers. Bioorg. Med. Chem. Lett. 19, 3128-3135 (2009).
138. Zhou, Y. et al. Pyrimido[5,4-e][1,2,4]triazine-5,7 (1H,6H)-dione derivatives as novel small molecule chaperone amplifiers. Bioorg. Med. Chem. Lett. 19, 4303-4307 (2009).
139. Zhang, B. et al. Identification of small-molecule HSF1 amplifiers by high content screening in protection of cells from stress induced injury. Biochem. Biophys. Res. Commun. 390, 925-930 (2009).
140. Hayashida, N. et al. Heat shock factor 1 ameliorates proteotoxicity in cooperation with the transcription factor NFAT. EMBO J. 29, 3459-3469 (2010).
141. Batista-Nascimento, L., Neef, D. W., Liu, P. C. C., Rodrigues-Pousada, C. & Thiele, D. J. Deciphering human heat shock transcription factor 1 regulation via post-translational modification in yeast. PLoS ONE 6, e15976 (2011).
142. Rimoldi, M., Servadio, A. & Zimarino, V. Analysis of heat shock transcription factor for suppression of polyglutamine toxicity. Brain Res. Bull. 56, 353-362 (2001). This study shows that constitutively active HSF1, via loss of repressive phosphorylation events, prevents protein aggregation in cell culture models of polyglutamine disease.
143. Banerjee Mustafi, S., Chakraborty, P. K. & Raha, S. Modulation of Akt and ERK1/2 pathways by resveratrol in chronic myelogenous leukemia (CML) cells results in the downregulation of Hsp70. PLoS ONE 5, e8719 (2010).
144. Khaleque, M. A. et al. Induction of heat shock proteins by heregulin β1 leads to protection from apoptosis and anchorage-independent growth. Oncogene 24, 6564-6573 (2005).
145. Xavier, I. et al. Glycogen synthase kinase 3β negatively regulates both DNA-binding and transcriptional activities of heat shock factor 1. J. Biol. Chem. 275, 29147-29152 (2000).
146. Anckar, J. et al. Inhibition of DNA binding by differential sumoylation of heat shock factors. Mol. Cell Biol. 26, 955-964 (2006).
147. Bernier-Villamor, V., Sampson, D. A., Matunis, M. J. & Lima, C. D. Structural basis for E2-mediated SUMO conjugation revealed by a complex between ubiquitin-conjugating enzyme Ubc9 and RanGAP1. Cell 108, 345-356 (2002).
148. Brunet Simioni, M. et al. Heat shock protein 27 is involved in SUMO-2/3 modification of heat shock factor 1 and thereby modulates the transcription factor activity. Oncogene 28, 3332-3344 (2009).
149. Fukuda, I. et al. Ginkgolic acid inhibits protein SUMOylation by blocking formation of the E1-SUMO intermediate. Chem. Biol. 16, 133-140 (2009).
150. Parker, J. A. et al. Resveratrol rescues mutant polyglutamine cytotoxicity in nematode and mammalian neurons. Nature Genet. 37, 349-350 (2005). This study shows that activation of SIR-2 (the C. elegans homolog of SIRT1) via resveratrol rescues neuronal dysfunction in C. elegans and mouse models of polyQ disease.
151. Kim, D. et al. SIRT1 deacetylase protects against neurodegeneration in models for Alzheimer's disease and amyotrophic lateral sclerosis. EMBO J. 26, 3169-3179 (2007).
152. Ladiwala, A. R. A. et al. Resveratrol selectively remodels soluble oligomers and fibrils of amyloid Aβ into off-pathway conformers. J. Biol. Chem. 285, 24228-24237 (2010).
153. Marambaud, P., Zhao, H. & Davies, P. Resveratrol promotes clearance of Alzheimer's disease amyloid-β peptides. J. Biol. Chem. 280, 37377-37382 (2005).
154. Lu, K.-T. et al. Neuroprotective effects of resveratrol on MPTP-induced neuron loss mediated by free radical scavenging. J. Agric. Food Chem. 56, 6910-6913 (2008).
155. Zhang, F. et al. Resveratrol protects dopamine neurons against lipopolysaccharide-induced neurotoxicity through its anti-inflammatory actions. Mol. Pharmacol. 78, 466-477 (2010).
156. Salamanca, H. H., Fuda, N., Shi, H. & Lis, J. T. An RNA aptamer perturbs heat shock transcription factor activity in Drosophila melanogaster. Nucleic Acids Res. 39, 6729-6740 (2011). This work describes an RNA aptamer that interacts with the DNA binding domain of HSF1 and inhibits its binding to promoter heat shock elements.
157. Liu, P. C. & Thiele, D. J. Modulation of human heat shock factor trimerization by the linker domain. J. Biol. Chem. 274, 17219-17225 (1999).
158. Finkbeiner, S. Bridging the Valley of Death of therapeutics for neurodegeneration. Nature Med. 16, 1227-1232 (2010).
159. Aguzzi, A. & O'Connor, T. Protein aggregation diseases: pathogenicity and therapeutic perspectives. Nature Rev. Drug Discov. 9, 237-248 (2010).
160. Hampel, H. et al. Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives. Nature Rev. Drug Discov. 9, 560-574 (2010).
161. Schapira, A. H. V. Challenges to the development of disease-modifying therapies in Parkinson's disease. Eur. J. Neurol. 18 (Suppl. 1), 16-21 (2011).
162. Murray, A. N., Solomon, J. P., Wang, Y. J., Balch, W. E. & Kelly, J. W. Discovery and characterization of a mammalian amyloid disaggregation activity. Protein Sci. 19, 836-846 (2010). This work describes the discovery of a mammalian disaggregase with the ability to disaggregate β-amyloid aggregates.
163. Opar, A. Hope builds for earlier detection of Alzheimer's disease. Nature Rev. Drug Discov. 9, 579-581 (2010).
164. Nielsen, P. A., Andersson, O., Hansen, S. H., Simonsen, K. B. & Andersson, G. Models for predicting blood-brain barrier permeation. Drug Discov. Today 16, 472-475 (2011).
165. Pardridge, W. M. Alzheimer's disease drug development and the problem of the blood-brain barrier. Alzheimers Dement. 5, 427-432 (2009).
166. Lipinski, C. A., Lombardo, F., Dominy, B. W. & Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 46, 3-26 (2001).
167. Cudkowicz, M. E. et al. Arimoclomol at dosages up to 300 mg/day is well tolerated and safe in amyotrophic lateral sclerosis. Muscle Nerve 38, 837-844 (2008).
168. Milane, A. et al. Brain and plasma riluzole pharmacokinetics: effect of minocycline combination. J. Pharm. Pharm. Sci. 12, 209-217 (2009).
169. Kumar, S. et al. Extracellular phosphorylation of the amyloid β-peptide promotes formation of toxic aggregates during the pathogenesis of Alzheimer's disease. EMBO J. 30, 2255-2265 (2011).
170. Williams, T. L. & Serpell, L. C. Membrane and surface interactions of the Alzheimer's Aβ peptide: insights into the mechanism of cytotoxicity. FEBS J. 278, 3905-3917 (2011).
171. Cohen, F. E. & Kelly, J. W. Therapeutic approaches to protein-misfolding diseases. Nature 426, 905-909 (2003).
172. Labbadia, J. et al. Altered chromatin architecture underlies progressive impairment of the heat shock response in mouse models of Huntington disease. J. Clin. Invest. 121, 3306-3319 (2011). This study demonstrates that activation of HSF1-dependent chaperone protein expression via an HSP90 inhibitor transiently ameliorates disease phenotypes in a mouse model of polyQ-based disease as a result of decreased promoter acetylation.
173. Balch, W. E., Morimoto, R. I., Dillin, A. & Kelly, J. W. Adapting proteostasis for disease intervention. Science 319, 916-919 (2008).
174. Biamonte, M. A. et al. Heat shock protein 90: inhibitors in clinical trials. J. Med. Chem. 53, 3-17 (2010).
175. Lancet, J. E. et al. Phase I study of the heat shock protein 90 inhibitor alvespimycin (KOS-1022, 17-DMAG) administered intravenously twice weekly to patients with acute myeloid leukemia. Leukemia 24, 699-705 (2010).
176. Nowakowski, G. S. et al. A phase I trial of twice-weekly 17-allylamino-demethoxy-geldanamycin in patients with advanced cancer. Clin. Cancer Res. 12, 6087-6093 (2006).
177. Brandt, G. E. L., Schmidt, M. D., Prisinzano, T. E. & Blagg, B. S. J. Gedunin, a novel Hsp90 inhibitor: semisynthesis of derivatives and preliminary structure-activity relationships. J. Med. Chem. 51, 6495-6502 (2008).
178. Kikuchi, T. et al. Cytotoxic and apoptosis-inducing activities of limonoids from the seeds of Azadirachta indica (neem). J. Nat. Prod. 74, 866-870 (2011).
179. Traynor, B. J. et al. Neuroprotective agents for clinical trials in ALS: a systematic assessment. Neurology 67, 20-27 (2006).
180. Bensimon, G. et al. Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study. Brain 132, 156-171 (2009).
181. Nanke, Y. et al. Geranylgeranylacetone, a non-toxic inducer of heat shock protein, induces cell death in fibroblast-like synoviocytes from patients with rheumatoid arthritis. Mod. Rheumatol. 19, 379-383 (2009).
182. Nishida, T. et al. Geranylgeranylacetone protects against acetaminophen-induced hepatotoxicity by inducing heat shock protein 70. Toxicology 219, 187-196 (2006).
183. Shirakabe, H. et al. Clinical evaluation of teprenone, a mucosal protective agent, in the treatment of patients with gastric ulcers: a nationwide, multicenter clinical study. Clin. Ther. 17, 924-935 (1995).